Overview of the clinical efficacy of investigational anticancer drugs

Journal of Internal Medicine

Volumn 253, Issue 1, 2003, Pages 46-75

  Nygren, P ^a   Larsson, R ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Clinical trials; Drug development

Indexed keywords

1 ACETYL 8 CARBAMOYLOXYMETHYL 3,9 EPOXY 5 FORMYL 1A,2,3,8,9,9A HEXAHYDRO 9 HYDROXY 7 METHOXY 1H AZIRINO[2,3 C][1]BENZAZOCINE ACETATE; 5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ANTINEOPLASTIC AGENT; BROSTALLICIN; CANFOSFAMIDE; CEMADOTIN; CP 461; CRYPTOPHYCIN 52; CT 2584; CYCLOSPORIN A; DIMESNA; ELACRIDAR; EP 0906; FB 642; FK 866; INDISULAM; IXABEPILONE; LAF 389; LANIQUIDAR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MCC 465; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; PIBROZELESIN; RO 31 7453; SB 408075; SGN 15; TARIQUIDAR; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; XR 5000; ZOSUQUIDAR;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037238780     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01098.x     Document Type: Review

References (277)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nature Rev Drug Disc 2002; 1: 493-502.
3. Atkins JH, Gershell LJ. Selective anticancer drugs. Nature Rev Drug Disc 2002; 1: 491-2.
4. Nygren P. What is cancer chemotherapy. Acta Oncol 2001; 40: 166-74.
5. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer. role of ATP-dependent transporters. Nature Rev Cancer 2002; 2: 48-58.
6. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem 2001; 36: 577-95.
7. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs 2002; 13: 181-209.
8. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nature Rev Cancer 2002; 2: 431-41.
9. Reed JC. Apoptosis-based therapies. Nature Rev Drug Disc 2002; 1: 111-21.
10. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nature Rev Cancer 2002; 2: 351-60.
11. Nottage M, Siu LL. Rationale for Ras and Raf-kinase as a target for cancer therapeutics. Curr Pharm Des 2002; 8: 2231-42.
12. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part I. J Clin Oncol 2002; 20: 2881-94.
13. Garber K. On the eve of protein destruction: ubiquitin research begins to pay off. J Natl Cancer Inst 2002; 94: 550-2.
14. Goss PE, Baker MA, Carver JP, Dennis JW. Inhibitors of carbohydrate processing: a new class of anticancer agents. Clin Cancer Res 1995; 9: 935-44.
15. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
16. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002; 3: 137-44.
17. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev Drug Disc 2002; 1: 287-99.
18. Karin M, Cao Y, Greten FR, Li Z-W. NF-Kappa B in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002; 2: 301-10.
19. McCormick F. Cancer gene therapy: fringe or cutting edge? Nature Rev Cancer 2001; 1: 130-41.
20. Tamm I, Dörken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489-97.
21. Bykov VJN, Issaeva N, Shilov A et al. Restoration of tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med 2002; 8: 282-8.
22. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2: 161-74.
23. Warrell RP Jr Differentiation agents. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2001; 489-95.
24. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Rev Drug Disc 2002; 1: 415-26.
25. Gasparini G. Metronomic scheduling: the future of chemotherapy. Lancet Oncol 2001; 2: 733-40.
26. Voest EE, Beerepoot LV, Groenewegen G et al. Phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer. Proc ASCO 2002; 21: A 322.
27. Herbst RS, Hess KR, Tran HT et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20: 3792-803.
28. Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Rev Cancer 2001; 1: 118-29.
29. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999; 17: 1047-60.
30. Jäger E, Jäger D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14: 178-82.
31. Jefford M, Marskovsky E, Cebon JS, Davis ID. The use of dendritic cells in cancer therapy. Lancet Oncol 2001; 2: 343-53.
32. Bell JC, Garson KA, Lichty BD, Stojdl DF. Oncolytic viruses: programmable tumour hunters. Curr Gene Ther 2002; 2: 243-54.
33. Bacik J, Camacho LH, Oshalim M, Spriggs DR. Whatever happened to that abstract? An analysis of presentation and publication of phase I trials, submitted to an oncology meeting. Proc ASCO 2001; 20: A 480.
34. Sekine I, Yamamoto N, Kunitoh H et al. Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. Ann Oncol 2002; 13: 1300-6.
35. Anonymous. Navigating the evolving world of drug discovery. Nature Rev Drug Disc 2002; 1: 3.
36. Garber K. Breaking the silence: the rise of epigenetic therapy. J Natl Cancer Inst 2002; 94: 874-5.
37. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nature Rev Cancer 2002; 2: 277-88.
38. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development. J Natl Cancer Inst 1999; 91: 1281-7.
39. List AF, Kopecky KJ, Willman CL et al. Benefit from cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Sothwest Oncology Group study. Blood 2001; 98: 3212-20.
40. Reyno L, Seymour L, Tu D et al. Phase III study of DPPE (BMS217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer (MBC): a National Cancer Institute of Canada (NCIC) study. Proc ASCO 2001; 20: A 118.
41. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug reistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224-32.
42. Joly F, Mangioni C, Nicoletto M et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc ASCO 2002; 21: A 806.
43. Anderson CP, Bailey HH, Matthay KK et al. Pilot of buthionine sulfoximine (BSO) combined with non-myeloablative melphalan (L-PAM) against refractory neuroblastoma (NB). Proc ASCO 2002; 21: A 1589.
44. Warner E, Hedley D, Andrulis I et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 1998; 6: 1451-7.
45. Gaynor ER, Unger JM, Miller TP et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. J Clin Oncol 2001; 19: 750-5.
46. Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 1993; 67: 1031-5.
47. Thomas H, Steiner JA, Mould GP et al. A phase IIA pharmacokinetic study of the P-glycoprotein inhibitor, XR9576 in combination with paclitaxel in patients with ovarian cancer. Proc ASCO 2001; 20: A 288.
48. Nuessler V, Scheulen ME, Oberneder R et al. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. Eur J Med Res 1997; 2: 55-61.
49. Faivre S, Brain E, Raymond E et al. A phase I dose-finding study of docetaxel-epirubicin combination given with a fixed dose of GF120918, a novel P-glycoprotein inhibitor, in patients with locally advanced and/or metastatic cancer. Proc ASCO 2002; 21: A 2139.
50. Warren KE, Patel MC, Aikin AA et al. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol 2001; 48: 275-82.
51. de Alwis DP, Pouliquen I, Burgess M et al. A phase I dose escalating study of LY335979, a novel Pgp modulator administered intravenously in combination with doxorubicin. Proc ASCO 2001; 20: A 284.
52. Dieras V, Degardin M, Benaoudia R et al. An EORTC/ECSG phase I and pharmacokinetics (PK) study of MS209 in combination with docetaxel in patients with progressive solid tumors. Proc AACR-NCI-EORTC Int Conf 2001: A 437.
53. van Zuylen L, Sparrebom A, van der Gaast A et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous adminstration of R101933. Eur J Cancer 2002; 38: 1090-9.
54. Larson RA, Boogaerts M, Estey E et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627-36.
55. Nabell L, Saleh M, Marshall J et al. Phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel for the treatment of metastatic breast and colo-rectal cancer. Proc ASCO 2002; 21: A 55.
56. Hart L, Redfern C, Srinivas S et al. A phase II study of SGN-15 (cBR96-doxorubicin immunoconjugate) combined with docetaxel in patients with hormone refractory prostate cancer. Proc ASCO 2002; 21: A 2433.
57. Matsumura Y, Gotoh M, Muro K et al. Phase I study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immuno-liposome tagged with a newly developed antibody, GAH, in patients with metastatic stomach cancer. Proc ASCO 2002; 21: A 1884.
58. Rowinsky EK, Ochoa L, Patniak A et al. SB-408075, a tumor-activated immunoconjugate targeting the C242 CanAg antigen with a potent maytansinoid payload: phase I, pharmacokinetic (PK) and biological studies. Proc ASCO 2002; 21: A 118.
59. Napier MP, Sharma SK, Springer CJ et al. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2001; 6: 765-72.
60. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-903.
61. Hough RE, Lorigan PC, Poynton C et al. A phase II protection study of BB-10010 in patients with DLBCL undergoing intensive chemotherapy. Proc ASCO 2001; 20: A 2675.
62. Takeda K, Negoro S, Matsui K et al. Phase I safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC): an Osaka phase I study group trial. Proc ASCO 2002; 21: A 453.
63. Cure H, Chevalier V, Adenis A et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 1175-81.
64. Giacchetti S, Bjarnason GA, Garufi C et al. First line infusion of 5-fluorouracil, leucovorin, oxaliplatin for metastatic colorectal cancer chronomodulated versus conventional delivery. A multicenter randomized trial of the EORTC chronomodulated group. Proc ASCO 2002; 21: A 2231.
65. von Pawel J, von Roemling R, Gatzemeier U et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung cancer. J Clin Oncol 2000; 18: 1351-9.
66. Bowman A, Izquierdo M, Jodrell D et al. Phase I clinical and pharmacokinetic (PK) study of the marine compound apli-dine (APL), administered as a 1 hour weekly infusion. Proc ASCO 2001; 20: A 476.
67. Dombret H, Fenaux P, Soignet S, Tallman MS. Established practice in the treatment of patients with acute promyelo-cytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39: 8-13.
68. Vuky JYuR, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 2002; 20: 327-30.
69. Delbado C, Lara PN, Vansteenkiste J et al. Phase II study of the novel epthilone BMS-227550 in patients (pts) with recurrent or metastatic non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc ASCO 2002; 21: A 1211.
70. Hovstadius P, Larsson R, Jonsson E et al. A phase I study of CHS 828 in patients with solid tumour malignancy. Clin Cancer Res 2002; 8: 2843-50.
71. Reese D, Carducci M, Petrylak D et al. A phase II trial of CT2584 in metastatic androgen-independent prostate cancer. Proc ASCO 2001; 20: A 2406.
72. Margolin K, Longmate J, Synold TW et al. Dolastatin-10 in metastatic melanoma: a phase II and pharmacokinetic trial of the California Cancer Consortium. Invest New Drugs 2001; 19: 335-40.
73. Cvetkovic RS, Figgitt DP, Plosker GL. ET-743. Drugs 2002; 62: 1185-92.
74. Goluboff ET, Prager D, Rukstalis D et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol 2001; 166: 882-6.
75. Mainwaring PN, Van Cutsem E, Van Laethem J-L et al. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Proc ASCO 2002; 21: A 611.
76. Culine S, Tombal B, Pozzo C et al. Randomized phase II trial of irofulven with or without prednisone in hormon-refractory prostate cancer (HRCP) patients (pts): preliminary results. Proc ASCO 2002; 21: A 2462.
77. Small EJ, Figlin R, Petrylak D et al. A phase II pilot study of KW-2189 in patients with advance renal cell carcinoma. Invest New Drugs 2000; 18: 193-7.
78. Kim WS, Kim MM, Choi HJ et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001; 19: 81-3.
79. Smyth J, Boneterrre ME, Schellens J et al. Acitivity of the dolastatin analogue, LU103793, in malignant melanoma. Ann Oncol 2001; 12: 509-11.
80. Stevenson JP, Sun W, Gallagher M et al. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on day 1 and 8 schedule every 21 days. Clin Cancer Res 2002; 8: 2524-9.
81. Plaxe SC, Blessing JA, Olt G et al. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer Chemother Pharmacol 2002; 50: 151-4.
82. Henner WD, Figlin RA, Garland LL et al. Phase 2 study of TLK286 (GSTP1-1 activated by glutathione analog) in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2002; 21: A 1249.
83. Caponigro F, Dittrich C, Sorenson JB et al. Phase II study of XR5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur J Cancer 2002; 38: 70-4.
84. Alberts DS, Floret S, Bentzen C. et al. Pharmacodynamic evaluation and determination of the recommended phase II dose and schedule of oral Apomine, a novel FXR nuclear receptor activator, in patients with advanced solid tumors. Proc AACR-NCI-EORTC Int Conf 2001: A 399.
85. Sun W, Stevenson JP, Redlinger M et al. Phase I clinical and pharmacokinetic (PK) trial of the novel pro-apoptotic compound CP-461 administered orally on a continuous twice-daily schedule to patients with advanced malignancies. Proc ASCO 2001; 20: A 459.
86. Calvert PM, O'Neill V, Twelves C et al. A phase I clinical and pharmacokinetic study of EP0906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc ASCO 2001; 20: A 429.
87. Britten CD, Delioukina M, Boulos L et al. A phase I and pharmacokinetic (PK) study of FB642 administered orally on daily schedule to patients with advanced solid tumors. Proc ASCO 2001; 20: A 2129.
88. Wolff RA, Wilding G, Carter S et al. Phase I study of FK317 in patients refractory solid tumors. Proc ASCO 2001; 20: A 377.
89. Holen KD, Burk K, Schwartz GK et al. Dose-finding and pharmacokinetic study of FK866, an inhibitor of NAD biosynthesis. Proc ASCO 2002; 21: A 346.
90. Schellens JHM, Rademaker-Lakhai JM, Horenblas S et al. Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen resistant prostate cancer. Proc ASCO 2002; 21: A 451.
91. Dutreix C, Dumez H, Giaccone G et al. Preliminary results of a phase I and pharmacokinetic study of LAF389 in adult patients with refractory tumors. Proc ASCO 2002; 21: A 367.
92. de Jonge MJ, ten Tije B, van der Gaast A et al. Phase I and pharmacokinetic (PK) study on PNU-166196, an novel minor groove (MGB) potentiated by glutathione (GSH) and GSH-transferase (GST), administered intravenously (iv) once every 3 weeks to patients (pts) with advanced cancer. Proc AACR-NCI-EORTC Int Conf 2001: A 714.
93. Cassidy J, Salazar R, Bisset D et al. A phase I clinical and pharmacokinetic study of Ro 31-7453 in patients with solid tumors: final report of 14-day q 4 weeks schedule. Proc AACR-NCI-EORTC Int Conf 2001: A 681.
94. Baselga J, Trigo JM, Bouhris J et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO 2002; 21: A 900.
95. Saltz L, Meropol NJ, Loeherer PJ, Waksal H, Needle MN, Mayer RJ. Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc ASCO 2002; 21: A 504.
96. Burtness BA, Flood YLW, Mattar BI, Forastiere AA. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). Proc ASCO 2002; 21: A 901.
97. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001; 344: 783-92.
98. Schwartz G, Dutcher JP, Vogelzang NJ et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EFG in renal cell cancer (RCC). Proc ASCO 2002; 21: A 91.
99. Hau P, Bogdahn U, Schulmeyer F et al. TGF-beta-2 antisense oligonucleotide AP12009 adminstered intratumorally to patients with malignant glioma in a clinical phaseI/II dose escalation study: safety and preliminary efficacy data. Proc ASCO 2002; 21: A 109.
100. Wersäll P, Ohlsson I, Biberfeld P et al. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 1997; 44: 157-64.
101. Tewes M, Schleucher N, Dirsch O et al. Results of a phase I trial of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72 000 in patients with EGFR expressing solid tumors. Proc ASCO 2002; 21: A 378.
102. Modjtahedi H, Hickish T, Nicolson M et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer 1996; 73: 228-35.
103. Chaudhry A, Carrasquillo JA, Avis IL et al. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 1999; 5: 3385-93.
104. Atkins MB, Hidalgo M, Stadler W et al. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc ASCO 2002; 21: A 36.
105. Nemunaitis J, Holmlund JT, Kraynak M et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinases C-alpha, in patients with advanced cancer. J Clin Oncol 1999; 17: 3586-95.
106. Tolcher AW, Reyno L, Venner PM et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2002; 8: 2530-5.
107. Cripps MC, Figueredo AT, Oza AM et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group study. Clin Cancer Res 2002; 8: 2188-92.
108. Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 18: 1728-33.
109. Hidalgo M, Siu LL, Neumanaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79.
110. Richardson PG, Barlogie B, Berenson J et al. Phase II study of the protasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease. Proc ASCO 2002; 21: A 40.
111. Johnston SRD, Hickish T, Houston S, Ellis PA, Howes AJ, Thibault A. Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc ASCO 2002; 21: A 138.
112. Harrousseau JL, Stone R, Thomas X et al. Interim results from a phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia. Proc ASCO 2002; 21: A 1056.
113. Cunningham D, deGramont A, Scheithauer W et al. Randomised double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc ASCO 2002; 21: A 502.
114. Van Cutsem E, Karasek P, Oettle H et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine+placebo in advanced pancreatic cancer (PC). Proc ASCO 2002; 21: A 517.
115. Druker BJ. STI571 (Gleevec/Glivec, imatinib) versus interferon + cytarabine as initial therapy for patients with CML. results of a randomized study. Proc ASCO 2002; 21: A 1.
116. Kris MG, Natale RB, Herbst RS et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who have failed platinum- and docetaxel-based regimens (IDEAL 2). Proc ASCO 2002; 21: A 1166.
117. Fukuoka M, Yano S, Giaccone G et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL 1). Proc ASCO 2002; 21: A 1188.
118. Natale RB, Skarin A, Maddox AM et al. Improvement in symptoms and quality of life from advanced non-small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc ASCO 2002; 21: A 1167.
119. Douillard JY, Giaccone G, Horai T et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAl 1). Proc ASCO 2002; 21: A 1195.
120. Gonzalez-Larriba JL, Giaccone G, Van Oosterom A et al. ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumors: final results of a phase I trial. Proc ASCO 2002; 21: A 376.
121. Wilkinson E. Surprise phase III failure for ZD1839. Lancet Oncol 2002; 3: 583.
122. Protheroe AS, Srinivasan M, Smith CL et al. A phase II trial of bryostatin-1 in patients with advanced renal cancer. Proc ASCO 2002; 21: A 2495.
123. Dowlati A, Payne J, Robertson K et al. Phase I trial of combination bryostatin-1 and vincristine in B-cell malignancies. Proc AACR-NCI-EORTC Int Conf 2001: A 800.
124. Schwartz GK, Ilson D, Saltz L et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19: 1985-92.
125. Bjarnason GA, Walde D, Whelan P, Chin J, Batist G. GD0039 in solid tumors. Proc ASCO 2002; 21: A 2494.
126. Chen HX, Marshall JL, Ness E et al. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res 2000; 6: 1259-66.
127. Woolley PV, Schultz CJ, Rodriguez GI et al. A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Invest New Drugs 1996; 14: 219-22.
128. Dang T, Johnson D, Kelly K, Rizvi N, Holmlund J, Dorr A. Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2001; 20: A 1325.
129. Evans TL, Fidias P, Skarin A et al. A phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibitor L-778,123 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 2002; 21: A 1861.
130. Propper DJ, McDonald AC, Man A et al. Phase I and pharmackinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485-92.
131. Sharma S, Kemeny N, Kelsen DP et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refrectory to 5-fluorouracil and irinotecan. Ann Oncol 2002; 13: 1067-71.
132. Lersch C, Van Cutsem E, Amado R et al. Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc ASCO 2001; 20: A 608.
133. Ko YJ, Small EJ, Kabbinavar F et al. A multi-institutional phase II study of SU101, a plateled-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 800-5.
134. Sausville EA, Arbuck SG, Messman R et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19: 2319-33.
135. Strumberg D, Bauer RJ, Moeller JG et al. Final results of a phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Proc ASCO 2002; 21: A 121.
136. Voi M, Taberno J, Cooper MR et al. A phase I study of the Farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (pts) with advanced solid tumors: clinical findings. Proc ASCO 2002; 21: A 312.
137. Mitchell DY, Reid JM, Parchment RE et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of the oral MEK inhibitor CI-1040, following multiple dose administration to patients with advanced cancer. Proc ASCO 2002; 21: A 320.
138. Adams VR, Bence AK, Anderson EB et al. A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects. Proc ASCO 2002; 21: A 374.
139. Rudin C, Bertucci DM, Strauss L et al. Liposome-encapsulated c-raf antisense oligodeoxynucleotide (LErafAON) in patients with advanced solid tumors: phase I study of weekly infusion. Proc ASCO 2002; 21: A 1845.
140. Herbst RS, Thornton DE, Kies MS et al. Phase 1 study of LLY317615, a protein kinase C inhibitor. Proc ASCO 2002; 21: A 326.
141. Crul M, Rosing H, de Klerk GJ et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 2002; 38: 1615-21.
142. Hutson TE, Mekhail T, Weiss P et al. Phase I study of Phenoxodiol given by constant intravenous infusion in patients with solid neoplasms refractory to standard therapy. Proc AACR 2002; 43: A 2750.
143. Murren JR, Papadimitrakopoulou VA, Sizer KC, Vaidyan-athan S, Ravera C, Abbruzzese JL. A phase I dose-escalating study to evaluate the biological activity and pharmacokinectics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc ASCO 2002; 21: A 377.
144. Goss PE, Baptiste J, Fernandes B, Baker M, Dennis JW. A phase I study of swainsonine in patients with advanced malignancies. Cancer Res 1994; 54: 1450-7.
145. Scher HI, Solit DB, Munster PN et al. Phase I. trial of 17AAG (17-allylamino 17-demethoxygeldanmycin) in patients (Pts) with advanced cancer. Proc AACR-NCI-EORTC Int Conf 2001; A 292.
146. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-40.
147. Prakash S, Foster BJ, Meyer M et al. Chronic oral adminstration of CI-994: a phase I study. Invest New Drugs 2001; 19: 1-11.
148. Richards DA, Waterhouse DM, Wagener DJT et al. Randomized, double-blind, placebo-controlled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994+G) versus placebo plus gemcitabine (P+G) in the treatment of patients with advanced pancreatic cancer (APC). Proc ASCO 2002; 21: A 644.
149. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 662-4.
150. Donehower R, Stewart D, Eisenhauer E, et al. A phase I and pharmacokinetic (PK) study of MG98, a human DNA methyltransferase (Dnmt) mRNA inhibitor, given as a 2-hour twice weekly (BIW) infusion 3 out of 4 wks. Proc AACR-NCI-EORTC Int Conf 2001; A 133.
151. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-83.
152. Thibault A, Smid D, Cooper MR et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer 1995; 75: 2932-8.
153. Kelly WK, Richon V, Troso-Sandoval T et al. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: biologic activity without toxicity. Proc ASCO 2001; 20: A 344.
154. Swisher SG, Roth JA, Neumanaitis J et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763-71.
155. Buckner JC, Malkin MG, Reed E et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) om patients with recurrent glioma. Mayo Clin Proc 1999; 74: 137-45.
156. Bishop MR, Iversen PL, Bayever E et al. Phase I trial of an antisense oligonucleotide OL (1) p53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-6.
157. Roth JA, Nguyen D, Lawrence DD et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-91.
158. Hao D, Rowinsky EK, Smetzer LA et al. A phase I and pharmacokinetic study of intravenous (IV) p53 gene therapy with RPR/INGN-201 in patients (pts) with advanced cancer. Proc ASCO 2001; 20: A 1045.
159. Buller RE, Runnebaum IB, Karlan BY et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-66.
160. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-401.
161. Villaret D, Glisson B, Kenady D et al. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002; 24: 661-9.
162. Gelmon K, Batist G, Chi K et al. A dose escalation phase I study of c-Myc antisense in combination with cisplatin in the treatment of solid tumours and lymphomas. Proc AACR-NCI-EORTC Int Conf 2001: A 801.
163. Freytag SO, Khil M, Stricker H et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-76.
164. Reichle A, Bross K, Vogt T et al. Pioglitazone and rofecoxib combined with angiostatic scheduling of chemotherapy in far advanced malignancies. Proc ASCO 2002; 21: A 19.
165. Kulke MH, Demetri GD, Sharpless NE et al. A phase II study of troglitazone, an activator of PPAR-gamma, in patients with chemotherapy-resistant metastatic colorectal cancer. Proc ASCO 2002; 21: A 2264.
166. Hirte HW, Vergote IB, Jeffrey JR et al. A international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/paclitaxel + platinum containing chemotherapy. Proc ASCO 2001; 20: A 843.
167. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24.
168. Sparano JP, Bernardo P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomised phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: an Eastern Cooperative Oncology Group trial. Proc ASCO 2002; 21: A 173.
169. King J, Clingan P, Morris DL. Placebo control double-blind randomised clinical trial of the matrix metalloproteinase inhibitor (MMP) marimastat in patients with inoperable colorectal cancer liver metastases (CRCLM): significant survival advantage in patients with musculoskeletal symptoms. Proc ASCO 2002; 21: A 537.
170. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-55.
171. Levin V, Phuphanic S, Glantz MJ et al. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloproteinase (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proc ASCO 2002; 21: A 100.
172. Bissett D, O'Byrne KJ, von Pawel J et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc ASCO 2002; 21: A 1183.
173. Levitt NC, Eskens FA, O'Byrne KJ et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001; 7: 1912-22.
174. Rudeck MA, Figg WD, Dyer V et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001; 19: 584-92.
175. Cianfrocca M, Cooley TP, Lee JY et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002; 20: 153-9.
176. Planting AST, van der Gaast A, Schöffski P et al. A phase I and pharmacokinetic (PK) study of the matrix metalloproteinase inhibitor (MMP), CP-471,358 in patients with advanced solid tumors. Proc ASCO 2002; 21: A 446.
177. Cheer SM, Forster RH. Alitretionin. Am J Clin Dermatol 2000; 1: 307-14.
178. Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2001; 14: 153-74.
179. Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000; 1: 251-2.
180. Keer HN, Reid T, Sreedharan S. Pivanex activity in refractory non-small cell lung cancer, a phase II study. Proc ASCO 2002; 21: A 1253.
181. Miles SA, Dezube BJ, Lee JY et al. Antitumor activity of oral 9-cis-retinoic acid in HIV associated Kaposi's sarcoma. AIDS 2002; 16: 421-9.
182. Bacoyiannis C, Dimopoulos MA, Kalofonos HP et al. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. Oncology 2002; 63: 130-8.
183. Jasti BR, LoRusso PM, Parchment RE et al. Phase I clinical trial of fenretinide (NSC374551) in advanced solid tumors. Proc ASCO 2001; 20: A 485.
184. Wieder R, Novick S, Hollis B et al. Pharmacokinetics and safety of ILX23-7553, a noncalcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Proc ASCO 2002; 21: A 2119.
185. Rizvi NA, Marshall JL, Ness E et al. Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol 2002; 20: 3522-32.
186. McCreery H, Schwartz G, Hammond LA et al. A phase I and pharmacokinetic (PK) study of Tazarotene (TZT), a potent retinoid with high selectivity for the retinoid acid receptor (RAR), on an uninterrupted, oral daily schedule in patients (pts) with solid malignancies. Proc ASCO 2001; 20: A 478.
187. Yang JC, Haworth L, Steinberg SM, Rosenberg SA, Novotny W. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc ASCO 2002; 21: A 15.
188. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
189. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin (C) + paclitaxel (P) + RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc ASCO 2001; 20: A 1256.
190. Jayson GC, Mulatero C, Ranson M et al. Anti-VEGF antibody HuMV833: an EORTC biological treatment development group phase I toxicity, pharmacokinetic and pharmacodyunamic study. Proc ASCO 2001; 20: A 14.
191. Weng DE, Weiss P, Kelackey C et al. Angiozyme pharmacokinetic and safety results: a phase I/II study in patients with refractory solid tumors. Proc ASCO 2001; 20: A 393.
192. Posey J, Ng T, Yang B et al. A phase I trial of an anti-KDR (VEGFR) chimeric antibody in patients with liver metastases in colorectal cancer (CRC). Proc ASCO 2002; 21: A 63.
193. Rosenthal MA, Rischin D, McArthur G et al. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 2002; 13: 770-6.
194. Zahalsky AJ, Wong RJ, Lis E et al. Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. Proc ASCO 2002; 21: A 902.
195. Tolcher A, Karp DD, O'Leary JJ et al. A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc ASCO 2002; 21: A 334.
196. Groen HJ, de Vries EG, Wynendaele W et al. PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study. Clin Cancer Res 2001; 12: 3928-33.
197. Yung WA, Friedman H, Jackson E et al. A phase I trial of PTK787/ZK 222584, a novel oral VEGFR TK inhibitor in recurrent glioblastoma. Proc ASCO 2002; 21: A 315.
198. Brahmer JR, Kelsey S, Scigalla P et al. A phase I study of SU6668 in patients with refractory solid tumors. Proc ASCO 2002; 21: A 335.
199. Hurwitz H, Holden SN, Eckhardt SG et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signalling, in patients with solid tumors. Proc ASCO 2002; 21: A 325.
200. Friedland D, Leon L, Manola J, Dutcher JP, Roth B, Wilding G. Carboxyamidotriazole (CAI) in patients with advanced renal cancer (RCC) refractory to immunotherapy: an ECOG phase II trial. Proc ASCO 2002; 21: A 2424.
201. Springgate CF, Cartwright T, Belt R, Redfern C, Stuart K. Phase II study of GBC-590 in patients with relapsing or refractory colorectal cancer. Proc ASCO 2001; 20: A 2226.
202. Bhargava P, Marshall JL, Dahut W et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiongenic agent, in patients with advanced cancers. Clin Cancer Res 2001; 7: 3912-9.
203. Gutheil JC, Campell TN, Pierce PR et al. Targeted antiangiongenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphabeta3. Clin Cancer Res 2000; 6: 3056-61.
204. De Vos FYFL, Hoekstra R, Gietema JA et al. A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-mimetic (ABT-510) in patients with advanced cancer. Proc ASCO 2002; 21: A 324.
205. Wamil BD, Thurman GB, Sundell HW et al. Soluble E-selectin in cancer patients as marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol 1997; 123: 173-9.
206. Gadgel SM, LoRusso PM, Wozniak AJ, Wheeler C. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. Proc ASCO 2002; 21: A 438.
207. Rocca A, Colleoni M, Masci G et al. Low dose oral methotrexate (MTX) and cyclophosphamide (CTX) in metastatic breast cancer (MBC): an attempt to exploit the antiangiogenic activity of common chemotherapeutic agents. Proc ASCO 2001; 20: A 116.
208. Engelsman E, Klijn JC, Rubens RD et al. Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Cooperative Group Phase III Trial (10808). Eur J Cancer 1991; 27: 966-70.
209. Batist G, Patenaude F, Champagne P et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002; 13: 1259-63.
210. Small EJ, Meyer M, Marshall E et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18: 1440-50.
211. Little RF, Wyvill KM, Pluda JM et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-602.
212. Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 404-14.
213. Tulpule A, Scadden DT, Espina BM et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 716-23.
214. Blumenschein GR, Fossella FV, Pisters KMW et al. A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc ASCO 2002; 21: A 1254.
215. Richardson PG, Schlossman RL, Weller E et al. Immuno-modulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-7.
216. Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-16.
217. Gollob JKV, Mier J, McDermott D, Atkins MB. Phase I trial of twice-weekly IV rhIL-12 plus low-dose SC IL-2 in patients with advanced malignancies. Proc ASCO 2002; 21: A 47.
218. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 15: 3554-61.
219. Punt C, Nagy A, Douillard J et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360: 671-7.
220. Fields ALA, Keller AM, Schwartzberg L et al. Edrecolomab (17-1A antibody) (EDR) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomised north american phase III study. Proc ASCO 2002; 21: A 508.
221. Leonard JP, Coleman M, Matthews JC et al. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data. Proc ASCO 2002; 21: A 1060.
222. Feldman EJ, Stone RM, Brandwein J et al. Phase III randomized trial of an anti-CD33 monoclonal antibody (HuM 195) in combination with chemotherapy compared with chemotherapy alone in adults with refractory or first-relapse acute myeloid leukemia (AML). Proc ASCO 2002; 21: A 1042.
223. Ehlen TG, Gordon AN, Fingert HJ et al. Adjuvant treatment with monoclonal antibody, OvaRex Mab-B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse (TTR) in a randomized, placebo-controlled study in patients (pts) with advanced epithelial ovarian cancer (EOC). Proc ASCO 2002; 21: A 31.
224. Coiffier B, Lepage E, Briére J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Eng J Med 2002; 346: 235-42.
225. Anonymous. Usefulness of a chimeric anti-GD2 (Ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study. Proc ASCO 1997; 16: A 1846.
226. Ball ED, Selvaggi K, Hurd D et al. Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15. Clin Cancer Res 1995; 1: 965-72.
227. Beck J, Mala C, Ullrich S, Mulders P. A phase I/II trial with monoclonal antibody WX-G250 in combination with low dose interleukin-2 in metastatic renal cell carcinoma. Proc AACR 2002; 43: A 4511.
228. Kushner BH, Kramer K, Cheung NV. Phase II trial of the anti-Gd2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001; 19: 4189-94.
229. Borchmann P, Schnell R, Davis T, Lewis LD, Diehl V, Engert A. The bispecific molecule H22xKI-4: phase I results and immunological findings in patients with Hodgkin's lymphoma. Ann Oncol 2002; 13 (Suppl. 2): Abstract 285.
230. de Bono JS, Forero A, Hammond LA et al. Safety, tolerability, and maximum tolerated dose of an intravenously administered human-engineered monoclonal antibody, ING-1 (heMab), in patients with advanced adenocarcinomas. Proc ASCO 2002; 21: A 34.
231. Milowsky MI, Rosmarin AS, Cobham MV et al. Anti-PSMA mAb huJ591 specifically targets tumor vascular endothelial cells in patients with advanced solid tumor malignancies. Proc ASCO 2002; 21: A 29.
232. Scott AM, Lee FT, Hopkins W et al. Specific targeting, biodistribution and lack of immunogeneity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol 2001; 19: 3976-87.
233. Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Eng J Med 2001; 345: 241-7.
234. Kreitman RJ, Wilson WH, White JD et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-36.
235. Fossella FV, Tolcher A, Elliott M et al. Phase I trial of the monoclonal antibody conjugate, BB-1091, for relapsed/refractory small cel lung cancer (SCLC) and other neuro-endocrine (NE) tumors. Proc ASCO 2002; 21: A 1232.
236. Kreitman R, Squires D, O'Hagan D et al. SS1 (dsFv)-PE38 anti-mesothelin immunotoxin in advanced malignancies: phase I study of continuous infusion. Proc ASCO 2002; 21: A 1896.
237. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin difitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 15: 376-88.
238. Kuzel T, Smith J, Urba W et al. IL13-PE38QQR cytotoxin in advanced renal cell carcinoma (RCC): phase I and phar-macokinetic study. Proc ASCO 2002; 20: A 1841.
239. Sampson JH, Reardon D, Akabani G et al. A phase I study of intratumoral infusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the pseudomonas exotoxin (TP-38) for the treatment of malignant brain tumors. Proc ASCO 2002; 21: A 1860.
240. Stopeck AT, Jones A, Hersh EM et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B27/beta2 microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7: 2285-91.
241. Richards J, Thompson J, Atkins MB et al. A controlled randomized phase III trial comparing the response to dacarbazine with and without Allovectin-7 (A) in patients with metastatic melanoma. Proc ASCO 2002; 21: A 1380.
242. Maxwell-Armstrong CA, Durrant LG, Buckley TJ et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001; 84: 1433-6.
243. Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacullus Calmette-Guerin. Clin Cancer Res 1999; 5: 1319-23.
244. Foon KA, Lutzky J, Baral RN et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000; 18: 376-84.
245. Batova A, Strother D, Castleberry R, Eskenazi AE, Yu AL. Immune response to an anti-idiotype monoclonal antibody 1A7 as a tumor vaccine in children with high risk neuroblastoma. Proc AACR 2002; 43: A 713.
246. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997; 3: 1267-76.
247. Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 2002; 3: 89-96.
248. Vermorken JB, Claessen AME, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-50.
249. Harris JE, Ryan L, Hoover HC et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283. J Clin Oncol 2000; 18: 148-57.
250. Sondak VK, Liu PY, Tuthill RJ et al. Adjuvant immunotherapy of resected, intermediate thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20: 2058-66.
251. James ND, Atherton PJ, Jones J, Howie AJ, Tchekmedyian S, Curnow RT. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer 2001; 20: 152-6.
252. Smith AM, Justin T, Michaeli D, Watson SA. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res 2000; 6: 4719-24.
253. Curnow RT. Clinical experience with CD-64-directed immunotherapy. An overview. Cancer Immunol Immunother 1997; 45: 210-5.
254. King D, Albertini M, Schalch H et al. Phase I/IB trial of the immunocytokine hu14.18-IL2 in patients with metastatic melanoma. Proc ASCO 2002; 21: A 62.
255. Agarwala SS, Glaspy J, O'Day SJ et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20: 125-33.
256. Paul S, Calmels B, Acres RB. Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. Curr Gene Ther 2002; 2: 91-100.
257. Corradini P, Tarella C, Olivieri A et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75-82.
258. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20: 1295-303.
259. Childs R, Srinivasan R. Advances in allogenic stem cell transplantation: directing graft-versus-leukemia at solid tumors. Cancer J 2002; 8: 2-11.
260. Margolin K, Atkins MB, Weber JS et al. Phase I study of BAY 50-4798, an interleukin-2 (IL-2) selective agonist, in refractory cancer patients. Proc AACR-NCI-EORTC Int Conf 2001: A 528.
261. Tchekmedyian S, Glasby J, Korman A, Keler T, Deo Y, Davis TA. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc ASCO 2002; 21: A 56.
262. Sakamoto J, Teramukai S, Watanabe Y et al. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. J Immunother 2001; 24: 250-6.
263. Ito K, Nakazato H, Takagi H et al. A randomized clinical trial on adjuvant immunochemotherapy with protein bound polysaccharide K (PSK) after curative resection of colon cancer: seven-year follow-up after surgery. Proc ASCO 2001; 20: A 2220.
264. Kato H, Konaka C, Tsuboi M et al. A randomized phase III study comparing ubenimex (Bestatin) versus placebo as a postoperative adjuvant treatment in patients with stag Isquamous cell lung cancer. Proc ASCO 2001; 20: A 1225.
265. Kobayashi T, Miyawaki S, Tanimoto M et al. Randomised trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996; 14: 204-13.
266. Ferreira A, Miller WE, McMillan R et al. A pilot study of GM-CSF following complete response to high-dose chemotherapy with autologous stem-cell rescue in stage IV breast cancer. Proc AACR 2002; 43: A 3736.
267. Vasey PA, Shulman LN, Campos S et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562-9.
268. Nemunaitis J, Khuri FR, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-98.
269. Fong Y, Kemeny N, Jarnagin W et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases. Proc ASCO 2002; 21: A 27.
270. Pecora AL, Rizvi N, Cohen GI et al. Phase I trial of intravenous adminstration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002; 20: 2251-66.
271. Morris DG, Forsyth PA, Paterson AH et al. A phase I trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc ASCO 2002; 21: A 92.
272. Altorki NK, Keresztes RS, Port JL et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. Proc ASCO 2002; 21: A 101.
273. Dickson J, Pittman K, Patterson K et al. A phase 1/2 trial of Lyprinol in advanced hormone refractory prostate cancer and hormone and chemotherapy refractory breast cancer. Proc ASCO 2002; 21: A 2154.
274. Schwartz GK, Budman DR, Endres S et al. Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPARgamma). Proc ASCO 2002; 21: A 343.
275. Carducci MA, Nelson JB, Humerickhouse R, Weinberg M, Schmitt J, Nabuls A. Effects on atrasentan on progression and survival in men with hormone refractory prostate cancer: follow-up to study M96-594. Proc ASCO 2002; 21: A 708.
276. Lissoni P, Barni S, Mandala M et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35: 1688-92.
277. Alderson L, Sampath P, Darnowski JW, Calabresi P. Phase I/II clinical and pharmacological studies with taurolidine in patients with recurrent glioblastoma multiforme. Proc ASCO 2001; 20: A 2061.